Stocks in News At a Glance: neogen chem., BOB, Vedanta…
Ahmedabad, 11 April
Shilpa Medicare: Company gets US FDA final nod for its ANDA, Apremilast tablets (Positive)
Bajaj Finserv: Mutual Fund files for five new MF schemes (Positive)
Zydus Lifesciences: Company gets final approval from US FDA for Azithromycin Tablets (Positive)
IRB Infra Developers’: March toll collection up 20.6% at Rs 369.9 cr Vs Rs 306.6 cr (YoY) (Positive)
JSW Steel: Company posted a 13% growth in its consolidated crude steel production at 6.58 million tonne (MT) during the fourth quarter of FY23. (Positive)
Kalpataru Power: Company receives new orders worth Rs 3,100 crore in March-April (Positive)
Fusion MicroFinance: AUM up 37% at Rs 9,296 cr Vs Rs 6,786 cr (YoY) (Positive)
Nagarjuna Fertilizer: Restarts Urea Production in Plant-II at Kakinada, Andhra Pradesh (Positive)
Thangamayil: Company to open its 54th branch at Kumbakonam, Tamil Nadu on Friday (Positive)
Neogen Chemicals: Company signs a landmark agreement with MU Ionic Solutions, Japan to acquire manufacturing technology license for electrolytes in India” (Neutral)
Nazara Tech/Delta Corp: Tamil Nadu Governor R.N Ravi approves Bill banning online gambling (Neutral)
Bank Of Baroda Q4: Total deposits up 15.1%, Global gross advances up 19% (YoY) (Neutral)
JSW Ispat Special Products Q4: Crude Steel production up 9% at 0.18 mt Vs 0.17 mt (YoY) (Neutral)
Vedanta: Company to consider issuance of NCDs on a private placement basis on April 13 (Neutral)
Schaeffler India: The Company will trade ex-dividend with effect from April 11. The company has announced final dividend of Rs 24 per share. (Neutral)
State Bank of India: The Bank said its Board will be meeting on April 18 to consider the long term fund raising up to $2 billion (Neutral)
MPS: Company to evaluate proposals for fund raising (Neutral)
HDFC Bank: Board will inter alia consider a proposal for recommendation of dividend on15th April (Neutral)
(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)
(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ, ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)
